癌症3期临床试验更新报告现状分析
该研究评估了1990至2010年间发表于6大期刊的207项乳腺癌、肺癌和前列腺癌药物随机对照试验,仅20%有更新报告。与更新显著相关的因素包括阳性结果、较大样本量、内分泌或靶向药物及辅助治疗。31项试验中主要终点风险比中位数从0.66升至0.74(P<.001),提示效果下降。
要点
- 仅20%的癌症3期RCT有更新报告,多数初始报告事件数少、数据不成熟。
- 阳性结果、大样本、内分泌/靶向药物及辅助治疗试验更易被更新。
- 更新后主要终点HR中位数从0.66升至0.74,提示疗效下降。
核心结论
- 仅20%的乳腺癌、肺癌和前列腺癌3期RCT有更新报告,初始报告基于较少事件且结果不成熟。
- 更新试验的更成熟数据显示治疗效果有所下降。
- 建议强制要求提供成熟长期结果的更新报告。
研究设计与样本
- 研究识别了1990至2010年间发表于6大期刊的207项两组RCT,样本量至少100,评估乳腺癌、肺癌或前列腺癌药物治疗。
- 检索PubMed和大型癌症会议摘要以识别截至2019年发表的同一试验的更新或更早报告。
- 使用逻辑回归识别与提供更新报告相关的因素,并比较初始与更新报告的主要和次要终点风险比。
主要发现
- 207项RCT中41项(20%)有更新报告。
- 与更新显著相关的因素包括阳性试验结果(OR 8.7,95%CI 3.3-23.3)、较大试验规模(OR 1.0006,95%CI 1.0000-1.0012)、评估内分泌药物(OR 5.8,95%CI 1.6-21.8)或靶向药物(OR 4.3,95%CI 1.3-14.6)相比化疗、以及评估辅助治疗而非晚期疾病治疗(OR 8.0,95%CI 2.9-21.9)。
- 31项试验的主要终点风险比中位数从初始的0.66(95%CI 0.22-1.20)增至更新的0.74(95%CI 0.32-1.19)(P<.001),表明有效性水平下降。
临床怎么用
- 临床医生应认识到癌症3期RCT初始报告可能基于不成熟数据,解读时应关注有无更新报告。
- 在决策中优先参考更新后的成熟数据,因其可能显示疗效下降。
- 支持强制要求临床试验提供长期更新报告以指导临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Phase 3 randomized clinical trials (RCTs) are usually reported after a predetermined number of events (death or disease progression) have occurred, when survival curves remain poorly defined. Updated reports are important in providing mature data. OBJECTIVES: To evaluate the proportion of phase 3 RCTs for cancer that are updated and the factors that are associated with updating them and, for updated trials, to compare initial and updated results. DESIGN, SETTING, AND PARTICIPANTS: This study identified reports of 2-group RCTs with a sample size of at least 100, published in 6 major journals between 1990 and 2010, that evaluated drug treatments for breast, lung, or prostate cancer. PubMed and abstracts of large cancer conferences were searched to identify updated (or earlier) reports of the same trials published up to 2019. Logistic regression was used to identify factors associated with the provision of updated reports. The hazard ratios defining the relative treatment effects for the primary and secondary end points between the initial and updated reports were compared. MAIN OUTCOMES AND MEASURES: Proportion of RCTs whose results are updated, factors associated with updating, and change in hazard ratio for the primary end point between initial and updated reports. RESULTS: A total of 207 RCTs met the inclusion criteria, and 41 (20%) were found to have updated reports. The factors significantly associated with an update included positive trial results (odds ratio [OR], 8.7 [95% CI, 3.3-23.3]), larger trial size (OR, 1.0006 [95% CI, 1.0000-1.0012]), evaluation of hormonal agents (OR, 5.8 [95% CI, 1.6-21.8]) or targeted agents (OR, 4.3 [95% CI, 1.3-14.6]) compared with chemotherapy, and evaluation of adjuvant therapy rather than therapy for advanced disease (OR, 8.0 [95% CI, 2.9-21.9]). For 31 trials for which initial and updated hazard ratios for the primary end point were available, the median hazard ratio increased from 0.66 (95% CI, 0.22-1.20) to 0.74 (95% CI, 0.32-1.19) (P < .001), indicating a decreased level of effectiveness. CONCLUSIONS AND RELEVANCE: Only 20% of reports of phase 3 clinical trials for breast, lung, and prostate cancer were updated. Original reports of such trials are based on relatively few events, and their results are immature; more mature data indicate a decreased level of effect in updated trials. Updated reporting to provide mature, long-term results of clinical trials should be mandated.
引用
- Elimova E, Moignard S, Li X, et al. Updating Reports of Phase 3 Clinical Trials for Cancer. JAMA Oncol. 2021. PMID: 33538777. doi:10.1001/jamaoncol.2020.6968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。